MARINOMED focuses on the development of innovative products based on patent-protected technology platforms in the field of respiratory and ophthalmological diseases. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose.

The Carragelose® platform comprises innovative patent-protected products targeting viral infections of the respiratory tract. Carragelose® directly binds to repiratory

viruses and creates a protective layer and therefore prohibits infection by viruses. It blocks the virus from attaching the cells. This ability has become very interesting due

to the actual pandemia. Carrageloses reduces SARS-CoV-2 virus replication by more than 99,99%. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold via international partners in over 40 countries worldwide. Further information is available at: www.marinomed.com After the presentation on company and ongoing research Dr. Grassauer answered questions of the members on the achievements and outlook of the company and on ways to overcome the current pandemy.